[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600587":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":43,"centralContacts":48,"locations":54,"responsibleParty":238,"collaborators":52,"id":240,"slug":241,"hasResults":242,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":52,"eligibilityCriteria":246,"healthyVolunteers":242,"sex":247,"minAge":248,"maxAge":52,"enrollmentInfo":249,"targetDuration":52,"studyType":252,"phases":253,"briefSummary":256,"conditions":257,"keywords":52,"overallStatus":56,"whyStopped":52,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":268},{"fullName":5,"class":6},"Nanjing Leads Biolabs Co.,Ltd","INDUSTRY",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"LBL-024","EXPERIMENTAL","Cohort 1 (LBL-024 monotherapy):\n\nSubjects received treatment with LBL-024 , intravenous infusion.",[13],"Drug: LBL-024 for Injection",{"label":15,"type":10,"description":16,"interventionNames":17},"LBL-024 + LBL-007 combination","Cohort 2 (LBL-024 + LBL-007 combination):\n\nSubjects received treatment with LBL-024 combined with LBL-007 , intravenous infusion.",[13,18],"Drug: LBL-007 Injection",{"label":20,"type":10,"description":21,"interventionNames":22},"LBL-024 + toripalimab combination","Cohort 3 (LBL-024 + toripalimab combination ):\n\nSubjects received treatment with LBL-024 combined with toripalimab , both intravenous infusion.",[13,23],"Drug: Toripalimab Injection",[25,31,37],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","LBL-024 for Injection","LBL-024 , Intravenous infusion.",[9,15,20],[9],{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"LBL-007 Injection","LBL-007 , intravenous infusion.",[15],[36],"LBL-007",{"type":26,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"Toripalimab Injection","Toripalimab , intravenous infusion.",[20],[42],"Toripalimab",[44],{"name":45,"affiliation":46,"role":47},"Yu Chen","Fujian Cancer Hospital","PRINCIPAL_INVESTIGATOR",[49],{"name":45,"role":50,"phone":51,"phoneExt":52,"email":53},"CONTACT","025-83378099",null,"maxy@leadsbiolabs.com",[55,71,84,94,106,118,130,142,154,166,178,189,202,214,226],{"facility":46,"status":56,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"RECRUITING","Fuzhou","Fujian","350014","China","CN",{"type":63,"coordinates":64},"Point",[65,66],119.30611,26.06139,{"lat":66,"lon":65},[69],{"name":70,"role":50,"phone":51,"phoneExt":52,"email":53},"yu chen",{"facility":72,"status":56,"city":73,"state":74,"zip":75,"country":60,"countryCode":61,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Sun Yat-sen University Cancer Center","Guangzhou","Guangdong","510060",{"type":63,"coordinates":77},[78,79],113.25,23.11667,{"lat":79,"lon":78},[82],{"name":83,"role":50,"phone":51,"phoneExt":52,"email":53},"Xiangyu Ma",{"facility":85,"status":86,"city":73,"state":74,"zip":87,"country":60,"countryCode":61,"cosmosGeoPoint":88,"geoPoint":90,"contacts":91},"Dermatology Hospital of Southern Medical University","NOT_YET_RECRUITING","510080",{"type":63,"coordinates":89},[78,79],{"lat":79,"lon":78},[92],{"name":93,"role":50,"phone":51,"phoneExt":52,"email":53},"xiangyu Ma",{"facility":95,"status":56,"city":96,"state":97,"zip":98,"country":60,"countryCode":61,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Guangxi Medical University Cancer Hospital","Nanning","Guangxi","530200",{"type":63,"coordinates":100},[101,102],108.31667,22.81667,{"lat":102,"lon":101},[105],{"name":83,"role":50,"phone":51,"phoneExt":52,"email":53},{"facility":107,"status":56,"city":108,"state":109,"zip":110,"country":60,"countryCode":61,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan","Hubei","430022",{"type":63,"coordinates":112},[113,114],114.26667,30.58333,{"lat":114,"lon":113},[117],{"name":83,"role":50,"phone":51,"phoneExt":52,"email":53},{"facility":119,"status":56,"city":120,"state":121,"zip":122,"country":60,"countryCode":61,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"Nanjing Drum Tower Hospital","Nanjing","Jiangsu","210009",{"type":63,"coordinates":124},[125,126],118.77778,32.06167,{"lat":126,"lon":125},[129],{"name":83,"role":50,"phone":51,"phoneExt":52,"email":53},{"facility":131,"status":86,"city":132,"state":133,"zip":134,"country":60,"countryCode":61,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"The First Hospital of Jilin University","Changchun","Jilin","130021",{"type":63,"coordinates":136},[137,138],125.32278,43.88,{"lat":138,"lon":137},[141],{"name":83,"role":50,"phone":51,"phoneExt":52,"email":53},{"facility":143,"status":56,"city":144,"state":145,"zip":146,"country":60,"countryCode":61,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"Shandong Cancer Hospital","Jinan","Shandong","250117",{"type":63,"coordinates":148},[149,150],116.99722,36.66833,{"lat":150,"lon":149},[153],{"name":83,"role":50,"phone":51,"phoneExt":52,"email":53},{"facility":155,"status":86,"city":156,"state":157,"zip":158,"country":60,"countryCode":61,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"Fudan University Shanghai Cancer Center","Shanghai","Shanghai Municipality","200032",{"type":63,"coordinates":160},[161,162],121.45806,31.22222,{"lat":162,"lon":161},[165],{"name":93,"role":50,"phone":51,"phoneExt":52,"email":53},{"facility":167,"status":56,"city":168,"state":169,"zip":170,"country":60,"countryCode":61,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"Shanxi Bethune Hospital","Taiyuan","Shanxi","030032",{"type":63,"coordinates":172},[173,174],112.56028,37.86944,{"lat":174,"lon":173},[177],{"name":83,"role":50,"phone":51,"phoneExt":52,"email":53},{"facility":179,"status":86,"city":180,"state":169,"zip":181,"country":60,"countryCode":61,"cosmosGeoPoint":182,"geoPoint":186,"contacts":187},"The Second Affiliated Hospital of Xi'an Jiaotong University","Xi’an","710004",{"type":63,"coordinates":183},[184,185],113.52486,35.99785,{"lat":185,"lon":184},[188],{"name":83,"role":50,"phone":51,"phoneExt":52,"email":53},{"facility":190,"status":56,"city":191,"state":192,"zip":193,"country":60,"countryCode":61,"cosmosGeoPoint":194,"geoPoint":198,"contacts":199},"West China Hospital of Sichuan University","Chengdu","Sichuan","610041",{"type":63,"coordinates":195},[196,197],104.06667,30.66667,{"lat":197,"lon":196},[200],{"name":201,"role":50,"phone":51,"phoneExt":52,"email":53},"xiangyu ma",{"facility":203,"status":86,"city":204,"state":205,"zip":206,"country":60,"countryCode":61,"cosmosGeoPoint":207,"geoPoint":211,"contacts":212},"Tianjin Medical University Cancer Institute &Hospital","Tianjin","Tianjin Municipality","300060",{"type":63,"coordinates":208},[209,210],117.17667,39.14222,{"lat":210,"lon":209},[213],{"name":83,"role":50,"phone":51,"phoneExt":52,"email":53},{"facility":215,"status":56,"city":216,"state":217,"zip":218,"country":60,"countryCode":61,"cosmosGeoPoint":219,"geoPoint":223,"contacts":224},"Yunnan Cancer Hospital","Kunming","Yunnan","650118",{"type":63,"coordinates":220},[221,222],102.71833,25.03889,{"lat":222,"lon":221},[225],{"name":201,"role":50,"phone":51,"phoneExt":52,"email":53},{"facility":227,"status":86,"city":228,"state":229,"zip":230,"country":60,"countryCode":61,"cosmosGeoPoint":231,"geoPoint":235,"contacts":236},"Zhejiang Cancer Hospital","Hangzhou","Zhejiang","310022",{"type":63,"coordinates":232},[233,234],120.16142,30.29365,{"lat":234,"lon":233},[237],{"name":83,"role":50,"phone":51,"phoneExt":52,"email":53},{"type":239,"investigatorFullName":52,"investigatorTitle":52,"investigatorAffiliation":52,"oldNameTitle":52,"oldOrganization":52},"SPONSOR","100600587","phase-1-a-trial-of-lbl-024-monotherapy-lbl-024-combined-with-lbl-007-or-toripalimab-in-patients-with-advanced-melanoma-100600587",false,"NCT07099430","A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma","An Open-label, Multicenter Phase Ib\u002FII Clinical Study to Evaluate the Efficacy and Safety of LBL-024 Monotherapy, LBL-024 in Combination With LBL-007 or Toripalimab in Patients With Advanced Melanoma","Inclusion Criteria:\n\n1. Agree to follow the trial treatment regimen, visit schedule,laboratory test, and comply with other requirements of the protocol, and voluntarily enroll in the study and sign the written informed consent.\n2. At the time of signing the informed consent form, the age was ≥ 18 years old, and the gender was not limited.\n3. The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\\~1.\n4. The expected survival time is at least 12 weeks.\n5. According to the evaluation of RECIST 1.1 （Response Evaluation Criteria in Solid Tumours）, the subjects enrolled have at least one measurable neoplasm lesion.\n6. Male of childbearing potential and Females of childbearing age are willing to take highly effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug.\n\nExclusion Criteria:\n\n1. Subjects who received live vaccination within 4 weeks before the first dose or were planned to receive live vaccination during the study period and 4 weeks after the dose.\n2. Major surgery or other treatment or diagnosis that has a significant impact on the subject within 4 weeks before the first dose.\n3. Patients with active, or who have had and have the possibility of recurrence of autoimmune diseases.\n4. History of severe cardiovascular and cerebrovascular disorder.\n5. Active infectious disease.\n6. History of mental illness (interfering with understanding or giving informed consent), drug abuse, alcoholism, or drug addiction.\n7. Women during pregnancy or lactation.\n8. The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study.","ALL","18 Years",{"count":250,"type":251},200,"ESTIMATED","INTERVENTIONAL",[254,255],"PHASE1","PHASE2","This study is an open-label, multicenter phase Ib\u002FII study to evaluate the efficacy and safety of LBL-024 monotherapy, LBL-024 in combination with LBL-007 or toripalimab in patients with advanced melanoma,To evaluate the preliminary efficacy and safety of LBL-024 monotherapy and combination therapy in patients with advanced melanoma.",[258],"Advanced Melanoma","2026-05-15",{"date":261,"type":262},"2026-05-18","ACTUAL",{"date":264,"type":262},"2025-09-05",{"date":266,"type":251},"2027-12-30",{"name":5,"class":6},15]